Critical role of lectin pathway mediated by MBL-associated serine proteases in complement activation for the pathogenesis in systemic lupus erythematosus.

Lupus nephritis MASPs Systemic lupus erythematosus

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 18 10 2022
revised: 04 07 2023
accepted: 09 08 2023
medline: 28 8 2023
pubmed: 28 8 2023
entrez: 28 8 2023
Statut: epublish

Résumé

In complement activation system, although the classical pathway has shown to play a critical role for the pathogenesis of SLE, the role of lectin pathway has remained unknown in the pathogenesis of SLE. As Mannose-binding lectin-associated serine proteases (MASPs) are associated with activation of the lectin pathway, we conducted this study to clarify MASPs associations in the pathogenesis of SLE. We evaluated the serum level of MASPs (MASP-1 and MASP-2) in total 68 SLE patients consisting of 15 patients with biopsy-confirmed membranous lupus nephritis (M-LN), 35 patients with biopsy-confirmed proliferative lupus nephritis (P-LN), and 18 SLE patients without LN (non-LN). Our data showed that the serum levels of MASPs were reduced in both P-LN and non-LN although those of M-LN were not reduced. Our data show that the lectin pathway mediated by MASPs plays a critical role for the pathogenesis of SLE except for M-LN.

Identifiants

pubmed: 37636359
doi: 10.1016/j.heliyon.2023.e19072
pii: S2405-8440(23)06280-1
pmc: PMC10457435
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e19072

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

J Rheumatol. 2015 Jun;42(6):948-51
pubmed: 25877499
N Engl J Med. 2009 Jul 2;361(1):11-21
pubmed: 19571279
Arthritis Res Ther. 2012 Oct 15;14(5):R218
pubmed: 23068019
Front Immunol. 2018 May 28;9:1191
pubmed: 29892304
J Cell Mol Med. 2020 Sep;24(18):10432-10443
pubmed: 32677764
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Immunol. 2010 Nov 1;185(9):5598-606
pubmed: 20870940
Transl Res. 2022 Jul;245:18-29
pubmed: 35296451
Immunohorizons. 2018 Sep;2(8):274-295
pubmed: 30417171
Arthritis Res Ther. 2020 Jun 9;22(1):138
pubmed: 32517774
Clin Exp Immunol. 2021 Jan;203(1):96-104
pubmed: 32681658
RMD Open. 2021 Dec;7(3):
pubmed: 34907023
Curr Rheumatol Rep. 2021 Feb 10;23(3):16
pubmed: 33569681
Front Immunol. 2019 Sep 23;10:2238
pubmed: 31608060
J Am Soc Nephrol. 2004 Feb;15(2):241-50
pubmed: 14747370
J Exp Med. 2010 Jan 18;207(1):29-37
pubmed: 20038603

Auteurs

Yuko Asanuma (Y)

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Kazuhisa Nozawa (K)

Department of Internal Medicine and Rheumatology, Juntendo University Koshigaya Hospital, Saitama, Japan.

Masakazu Matsushita (M)

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Makio Kusaoi (M)

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Yoshiyuki Abe (Y)

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Ken Yamaji (K)

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Naoto Tamura (N)

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Classifications MeSH